Filing Flows › Comparisons › AQST vs PRAX
Aquestive Therapeutics vs Praxis Precision Medicines: AQST and PRAX compared
Aquestive Therapeutics is the larger company: $7.6M of revenue in its latest quarter (Q3 2026) against $7.5M for Praxis Precision Medicines (Q4 2024). Praxis Precision Medicines is growing faster (14× against -41% a year earlier). Aquestive Therapeutics is more profitable, with an operating margin of -191.5% against -857.0%.
Where the money goes: AQST and PRAX
Aquestive Therapeutics (AQST) · Q3 2026
Aquestive Therapeutics, Q3 2026: revenue $7.6M (-41% year over year), operating margin -191.5%, net loss $16.5M, operating cash flow −$7.0M. The chart follows the revenue to costs, profit and cash.
Praxis Precision Medicines (PRAX) · Q4 2024
Praxis Precision Medicines, Q4 2024: revenue $7.5M (14× year over year), operating margin -857.0%, net loss $58.7M, operating cash flow −$56.1M. The chart follows the revenue to costs, profit and cash.
| Aquestive Therapeutics (AQST) | Praxis Precision Medicines (PRAX) | |
|---|---|---|
| Latest quarter | Q3 2026 | Q4 2024 |
| Revenue | $7.6M | $7.5M |
| Revenue growth, Y/Y | -41% | 14× |
| Operating margin | -191.5% | -857.0% |
| Net earnings | −$16.5M | −$58.7M |
| Net margin | -218.3% | -786.3% |
| Operating cash flow | −$7.0M | −$56.1M |
| Market value | — | $8.3B |
| Analysts’ mean target | — | $650.00 |
Where the revenue comes from
Aquestive Therapeutics
- Manufacture and supply revenue: $6.7M (88%)
- License and Royalty Revenue: $824K (11%)
- Co-development and research fees: $74K (1%)
Questions
Which is bigger, Aquestive Therapeutics or Praxis Precision Medicines?
Aquestive Therapeutics is the larger company: $7.6M of revenue in its latest quarter (Q3 2026) against $7.5M for Praxis Precision Medicines (Q4 2024).
Is Aquestive Therapeutics or Praxis Precision Medicines growing faster?
Praxis Precision Medicines is growing faster (14× against -41% a year earlier).
Which is more profitable, Aquestive Therapeutics or Praxis Precision Medicines?
Aquestive Therapeutics is more profitable, with an operating margin of -191.5% against -857.0%.
More: Aquestive Therapeutics earnings · how Aquestive Therapeutics makes money · Praxis Precision Medicines earnings · how Praxis Precision Medicines makes money
From the companies' latest 10-Q, 10-K or earnings release (10-Q filed Nov 3, 2026; 10-K filed Feb 28, 2025). Fiscal quarters can end on different dates. Not investment advice.